TRAUMA
Zoledronic acid affects men and women similarly in increasing bone mass after hip fracture
J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 211619 women and 508 men who underwent surgical repair for low-trauma hip fractures were randomized to either receive zoledronic acid (ZOL) or a placebo to determine the impact of ZOL on bone mineral density (BMD) in men and women surgical repair of hip fractures. Following assessments measured over 2 years, there were similar increases in the bone mass at the hip and femoral neck among both men and women treated with ZOL.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
